E-viri
PDF
Recenzirano
Odprti dostop
-
Jayk Bernal, Angélica; Gomes da Silva, Monica M; Musungaie, Dany B; Kovalchuk, Evgeniy; Gonzalez, Antonio; Delos Reyes, Virginia; Martín-Quirós, Alejandro; Caraco, Yoseph; Williams-Diaz, Angela; Brown, Michelle L; Du, Jiejun; Pedley, Alison; Assaid, Christopher; Strizki, Julie; Grobler, Jay A; Shamsuddin, Hala H; Tipping, Robert; Wan, Hong; Paschke, Amanda; Butterton, Joan R; Johnson, Matthew G; De Anda, Carisa
The New England journal of medicine, 02/2022, Letnik: 386, Številka: 6Journal Article
Oral outpatient treatment for Covid-19 is needed. In this phase 3, double-blind, randomized, controlled trial, molnupiravir, a small-molecule antiviral, was studied in unvaccinated patients with less than 5 days of Covid-19 illness. By day 29, hospitalization for progression of Covid-19 was lower with molnupiravir (6.8%) than with placebo (9.7%).
